title: 12 hours after cerebral ischemia is the optimal time for bone marrow mesenchymal stem cell transplantation.
abstract: Cell therapy using stem cell transplantation against cerebral ischemia has been reported. However, it remains controversial regarding the optimal time for cell transplantation and the transplantation route. Rat models of cerebral ischemia were established by occlusion of the middle cerebral artery. At 1, 12 hours, 1, 3, 5 and 7 days after cerebral ischemia, bone marrow mesenchymal stem cells were injected via the tail vein. At 28 days after cerebral ischemia, rat neurological function was evaluated using a 6-point grading scale and the pathological change of ischemic cerebral tissue was observed by hematoxylin-eosin staining. Under the fluorescence microscope, the migration of bone marrow mesenchymal stem cells was examined by PKH labeling. Caspase-3 activity was measured using spectrophotometry. The optimal neurological function recovery, lowest degree of ischemic cerebral damage, greatest number of bone marrow mesenchymal stem cells migrating to peri-ischemic area, and lowest caspase-3 activity in the ischemic cerebral tissue were observed in rats that underwent bone marrow mesenchymal stem cell transplantation at 12 hours after cerebral ischemia. These findings suggest that 12 hours after cerebral ischemia is the optimal time for tail vein injection of bone marrow mesenchymal stem cell transplantation against cerebral ischemia, and the strongest neuroprotective effect of this cell therapy appears at this time.
authors.affiliation: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran ; Cell and Molecular Medicine Student Research Group, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran ; Stem Cell Laboratory, Department of Anatomy, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Seyed Mojtaba
authors.initials: SM
authors.lastname: Hosseini
authors.affiliation: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran ; Cell and Molecular Medicine Student Research Group, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Farahmandnia
authors.affiliation: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran ; Cell and Molecular Medicine Student Research Group, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Razi
authors.affiliation: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran ; Cell and Molecular Medicine Student Research Group, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Somayeh
authors.initials: S
authors.lastname: Delavarifar
authors.affiliation: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran ; Cell and Molecular Medicine Student Research Group, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Benafsheh
authors.initials: B
authors.lastname: Shakibajahromi
keywords: bone marrow mesenchymal stem cells; cell therapy; cerebral ischemia; middle cerebral artery occlusion; nerve regeneration; neuroprotection; tail vein injection